Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Anneliese Dodds, MP for Oxford East & Chair of the Labour Party, visited the University of Oxford to learn more about the impactful work happening across departments in the field of cancer research.

Anneliese Dodds MP visits the CRUK Cancer Centre
Anneliese Dodds MP visits the CRUK Cancer Centre

Anneliese Dodds, MP for Oxford East & Chair of the Labour Party, visited the Cancer Research UK Oxford Centre at the University of Oxford on the 26 November 2021 to tour the labs and buildings where cutting-edge cancer research is being undertaken, to drive patient-focused solutions to cancer challenges.

Anneliese engaged with researchers from across Oxford’s key cancer themes: the areas where Oxford academics are making the biggest impact through major scientific developments.

The visit formed part of a Cancer Research UK campaign to engage MPs in the important and impactful cancer research happening in cancer centres across the UK.

During Anneliese’s visit, she viewed demonstrations from across a range of scientific disciplines, beginning with a talk from our Early Detection theme. Anneliese met with Chunxiao Song at the Target Delivery Institute, whose TAPS technology is a major advancement in the field of early detection through simple and cheap blood-based testing.

Anneliese talking with Chunxiao Song, who works on TAPS: an early detection of cancer technology that uses blood-based testingAnneliese talking with Chunxiao Song, who works on TAPS: an early detection of cancer technology that uses blood-based testing Anneliese viewing cancer big data information presented by Eva Morris, Jens Rittscher and Sharib AliAnneliese viewing cancer big data information presented by Eva Morris, Jens Rittscher and Sharib Ali

 Anneliese went on to meet with theme leaders from our Cancer Big Data activity happening at the Big Data Institute. They discussed the important work happening through the use of electronic health records to identify and address health inequalities and improve the health care system. Followed by a demonstration of the work using AI to detect cancer in novel way, such as its applications in identifying oesophageal cancer through endoscopy videos. 

Anneliese viewing work at the IBME with Laura Spiers and Tamsyn Clarke - who are working on improving cancer drug delivery through the physical sciencesAnneliese viewing work at the IBME with Laura Spiers and Tamsyn Clarke - who are working on improving cancer drug delivery through the physical sciences Anneliese talking with clinical researcher Sarah Blagden about the scope of cancer clinical trials happening in OxfordAnneliese talking with clinical researcher Sarah Blagden about the scope of cancer clinical trials happening in Oxford

The tour also touched on the vital work of the physical sciences, such as researchers from the PanDox trial at the Institute for Biomedical Engineering who are applying novel engineering approaches to improve the delivery of drugs in a more targeted way. Before ending on the clinical applications of all this work which are being delivered through the important clinical trials units at the Oxford University Hospitals NHS Foundation Trust, which are dedicated to testing new and improved treatments for cancer.

 

It was fantastic to see the diversity of disciplines here in Oxford that are contributing to ongoing improvements in cancer patient care. There are some cutting-edge projects happening that will ultimately benefit many through cancer early detection, diagnosis and treatment.

This tour has underlined that Oxford and the wider UK can be a science superpower. To do this the UK Government must invest in the thriving life sciences sector, in order to deliver on its commitments to those affected by cancer.- Anneliese Dodds, MP for Oxford East & Chair of the Labour Party


Similar stories

Machine Learning Predicts SETD2 Mutation Status with Unprecedented Accuracy using DNA methylation

In a pan-cancer analysis spanning 24 different cancer type, researchers shed light on the critical role of SETD2 in tumourigenesis.

Oxford to launch UK’s first trials unit dedicated to conducting precision prevention and early detection studies

Oxford researchers have been given a £1 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.

Multi-cancer blood test shows real promise in NHS trial

An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.

The Howat Foundation to fund Chair in Clinical Oncology

Oxford Cancer announce the endowment of a Chair in Clinical Oncology, thanks to generous philanthropic support from The Howat Foundation

New Oxford and Nottingham developed tool uses existing health records to predict people’s risk of developing lung cancer within the next 10 years

A team of researchers from the University of Oxford and the University of Nottingham have developed a new tool, called ‘CanPredict’, aimed at identifying the people most at risk of developing lung cancer over the next 10 years, and put them forward for screening tests earlier, saving time, money and, most importantly, lives.

Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.